| 11:00- noon || |
Session 3A (VC Stream) The Life Sciences Century: Investing in the Perfect Hedge
Health care expenditures in developed economies are expected to grow three times faster than GDP over the next two decades. Public pensions, private employers and national health systems are quickly becoming overwhelmed by the cost of providing healthcare benefits to workers and pensioners. On top of this burden are the mounting losses to productivity resulting from a population that’s increasingly overweight, aging and suffering from costly chronic conditions such as heart disease and diabetes.
Savvy institutional investors are realizing they can hedge against these looming financial threats by investing today in innovative life sciences companies whose products and services lower the cost of healthcare that they themselves must ultimately bear. And, as industries like information technology mature, healthcare is gaining the attention of investors hungry for growth returns. The panelists will discuss some of the most compelling opportunities for life sciences investing in the new century.
Stephen Hurwitz, Partner, Choate Hall & Stewart LLP
Gerald Quirk, Partner and Co-Chair, Choate Hall & Stewart LLP
David Allan, Chairman, Stem Cell Therapeutics
Gerry Brunk, Managing Director, Lumira Capital
Dr. Maurice R. Ferré, President, Chief Executive Officer, Chairman of the Board of Directors, MAKO Surgical Corp.
Thomas G. Wellner, President and Chief Executive Officer, CML HealthCare Inc